Avalyn Pharma Inc. AVLN
Set alert
26.07 USD +0.46 +1.82%
As of Nov 3, 12:58 PM ET
25.45 Day range 26.82
22.24 52-week range 40.17
- YTD
- -11.61%
- 1 year
- -11.61%
- Open
- 25.87
- Prev close
- 25.60
- Mkt cap
- 1.16B
- Vol
- 223.70K
- Avg vol
- 289.84K
- EPS
- -2.47
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.45
- High
- 26.82
- Forward P/E
- -9.92
- Beta
- 0.00
- Short ratio
- 7.21
- Inst. own
- 104.07%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 30.16
- 200-d avg
- 29.99
- 1y target
- 61.80
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 61.80 +137.1% upside
Now 26.07
- Target (low)
- 52.00
- Target (mean)
- 61.80
- Target (high)
- 80.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.75 | -0.79 – -0.71 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next quarter | -0.72 | -0.72 – -0.72 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Current year | -2.69 | -2.69 – -2.69 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Next year | -2.58 | -2.58 – -2.58 | -2.69 | +4.1% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Raymond James | Initiated | — | Outperform |
| Aug 13, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 26, 2026 | Evercore ISI Group | Initiated | — | Outperform |
| May 26, 2026 | Guggenheim | Initiated | — | Buy |
| May 26, 2026 | Morgan Stanley | Initiated | — | Overweight |